Catalent to Acquire Cook Pharmica for US$950 Million


Fried Frank acted as counsel to Catalent (NYSE: CTLT) in its announced agreement to acquire Cook Pharmica for US$950 million, with US$750 million to be paid at closing and the balance to be paid in equal installments, without interest, on each of the next four anniversaries of the closing. The acquisition will strengthen Catalent's position as a leader in the rapidly growing area of biologics development and analytical services, manufacturing, and finished product supply. The transaction is expected to close in the fourth quarter of this year, subject to customary closing conditions. Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. Cook Pharmica is an integrated provider of drug substance and drug product manufacturing and related services. 
The Fried Frank team was led by corporate partners Steven Epstein and Matthew V. Soran and included corporate partners Daniel J. Bursky, Joshua Thomas Coleman, and Michael T. Gershberg; antitrust partner Nathaniel L. Asker; executive compensation & ERISA partner Adam Kaminsky; litigation partners Scott B. Luftglass and Joshua D. Roth; tax partner Michael J. Alter; corporate special counsel Howard A. Fine; corporate real estate special counsel Jessica H. Mayes; environmental special counsel Donna Mussio; intellectual property & technology special counsel Amir R. Ghavi; corporate associates Samuel  A. Borland, Dallas Cruz, Jennifer Edelson, Jonathan D. Frisby, Caitlin M. Hyduke, Shant P. Manoukian, Jose R. Morales, Hana Nah, Justin A. Schenck, Charles Stern and Joshua Teitler; environmental associates Samuel K. Dykstra and Mary Beth Phipps; executive compensation & ERISA associate Samantha J. Steinfeld; intellectual property & technology associate Alana C. Berrocal; litigation associate Harrison D. Polans; tax associates Ryan L. Conley and corporate law clerk Arielle D. Matza.